In vivo^{31} P nuclear magnetic resonance (<tex-math>${}^{31}{\rm P}\ {\rm NMR}$</tex-math>) spectroscopy has been used to compare metabolic profiles with tumor radiosensitivity. A radioresistant mammary carcinoma (MCa) and a radiosensitive methylcholanthrene-induced fibrosarcoma (Meth-A) were studied by^{31} P NMR spectroscopy in the tumor volume range of approximately <tex-math>$100-1200\ {\rm mm}^{3}$</tex-math>. The MCa showed a constant pH in this volume range; the ratio of phosphocreatine to inorganic phosphate (<tex-math>${\rm PCr}/P_{{\rm i}}$</tex-math>) for <tex-math>$160-300\ {\rm mm}^{3}$</tex-math> tumors was 0.33 ± 0.11 (mean ± standard deviation) and did not change (0.29 ± .09) for tumors in the volume range of <tex-math>$600-1200\ {\rm mm}^{3}$</tex-math>. In comparison, the Meth-A showed a decrease in tumor pH as volume increased from <tex-math>$160-300\ {\rm mm}^{3}$</tex-math> (pH 7.16 ± .04) to <tex-math>$600-1200\ {\rm mm}^{3}$</tex-math> (pH 6.94 ± .07). Tumor <tex-math>${\rm PCr}/P_{{\rm i}}$</tex-math> decreased from 0.70 ± .16 (<tex-math>$160-300\ {\rm mm}^{3}$</tex-math>) to 0.33 ± .16 (<tex-math>$600-1200\ {\rm mm}^{3}$</tex-math>). The radiation doses for control of MCa-induced tumors in 50% of the treated tumors ranged from 65 (<tex-math>$150-250\ {\rm mm}^{3}$</tex-math>) to 71 Gy (<tex-math>$1000-1300\ {\rm mm}^{3}$</tex-math>) and for the Meth-A-induced tumors ranged from 35 (<tex-math>$150-250\ {\rm mm}^{3}$</tex-math>) to 38 Gy (<tex-math>$1000-1300\ {\rm mm}^{3}$</tex-math>). These results suggest that^{31} P NMR spectra may be a qualitative predictor of tumor hypoxia, although further studies of human and rodent tumors are necessary to support this hypothesis.

Skip Nav Destination
#
Changes in

Close

Article navigation

March 1990

Research Article|
March 01 1990

#
Changes in ^{31}P Nuclear Magnetic Resonance with Tumor Growth in Radioresistant and Radiosensitive Tumors

*Radiat Res*(1990) 121 (3): 312–319.

Citation

J. A. Koutcher, A. A. Alfieri, D. C. Barnett, D. C. Cowburn, A. B. Kornblith, J. H. Kim; Changes in ^{31}P Nuclear Magnetic Resonance with Tumor Growth in Radioresistant and Radiosensitive Tumors. * Radiat Res* 1 March 1990; 121 (3): 312–319. doi: https://doi.org/10.2307/3577782

Download citation file:

Close

## Sign in

Don't already have an account? Register

### Client Account

You could not be signed in. Please check your email address / username and password and try again.

### Sign in via your Institution

Sign in via your Institution### Citing articles via

Commonalities Between COVID-19 and Radiation Injury

Carmen I. Rios, David R. Cassatt, Brynn A. Hollingsworth, Merriline M. Satyamitra, Yeabsera S. Tadesse, Lanyn P. Taliaferro, Thomas A. Winters, Andrea L. DiCarlo

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Pataje G. Prasanna, Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, Silvia C. Formenti, Chandan Guha, Dale J. Hu, Mohammad K. Khan, David G. Kirsch, Sunil Krishnan, Wolfgang W. Leitner, Brian Marples, William McBride, Minesh P. Mehta, Shahin Rafii, Elad Sharon, Julie M. Sullivan, Ralph R. Weichselbaum, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Kathryn D. Held

Photon GRID Radiation Therapy: A Physics and Dosimetry White Paper from the Radiosurgery Society (RSS) GRID/LATTICE, Microbeam and FLASH Radiotherapy Working Group

Hualin Zhang, Xiaodong Wu, Xin Zhang, Sha X. Chang, Ali Megooni, Eric D. Donnelly, Mansoor M. Ahmed, Robert J. Griffin, James S. Welsh, Charles B. Simone, II, Nina A. Mayr

Germicidal Efficacy and Mammalian Skin Safety of 222-nm UV Light

Manuela Buonanno, Brian Ponnaiya, David Welch, Milda Stanislauskas, Gerhard Randers-Pehrson, Lubomir Smilenov, Franklin D. Lowy, David M. Owens, David J. Brenner